Fibrosis and cardiac function in obesity: A randomised controlled trial of aldosterone blockade

Heart

Volumn 99, Issue 5, 2012, Pages 320-326

  Kosmala, Wojciech ^a   Przewlocka Kosmala, Monika ^a   Szczepanik Osadnik, Hanna ^a   Mysiak, Andrzej ^a   Marwick, Thomas H ^b,c  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF TASMANIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROCOLLAGEN C PROTEINASE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA1;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BODY MASS; COMORBIDITY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ELECTROCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE DIASTOLIC FUNCTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE SYSTOLIC FUNCTION; HEART MUSCLE FIBROSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE; UNIVERSITY HOSPITAL;

BODY MASS INDEX; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; FIBROSIS; FOLLOW-UP STUDIES; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MYOCARDIUM; OBESITY; PROSPECTIVE STUDIES; SPIRONOLACTONE; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84874105560     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-303329     Document Type: Article

References (30)

1. Gregg EW, Cheng YJ, Cadwell BL, et al. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA 2005; 293:1868-74.
2. Prevalence of overweight, obesity, and extreme obesity among adults: United States, trends 1960-1962 through 2007-2008. June 2010. http://www.cdc.gov/nchs/data/hestat/obesity-adult-07-08/obesity-adult-07-08.htm (accessed 29 May 2012).
3. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347:305-13.
4. Flegal KM, Graubard BI, Williamson DF, et al. Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA 2007; 298:2028-37.
5. Pischon T, Boeing H, Hoffmann K, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008; 359:2105-20.
6. Di Bello V, Santini F, Di Cori A, et al. Relationship between preclinical abnormalities of global and regional left ventricular function and insulin resistance in severe obesity: a color Doppler imaging study. Int J Obes (Lond) 2006; 30:948-56.
7. Wong CY, O'Moore-Sullivan T, Leano R, et al. Alterations of left ventricular myocardial characteristics associated with obesity. Circulation 2004; 110:3081-7.
8. Kosmala W, Plaksej R, Przewlocka-Kosmala M, et al. Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function. Int J Obes (Lond) 2008; 32:763-71.
9. Quilliot D, Alla F, Böhme P, et al. Myocardial collagen turnover in normotensive obese patients: relation to insulin resistance. Int J Obes (Lond) 2005; 29:1321-8.
10. Leopoldo AS, Sugizaki MM, Lima-Leopoldo AP, et al. Cardiac remodeling in a rat model of diet-induced obesity. Can J Cardiol 2010; 26:423-9.
11. Zaman AK, Fujii S, Goto D, et al. Salutary effects of attenuation of angiotensin II on coronary perivascular fibrosis associated with insulin resistance and obesity. J Mol Cell Cardiol 2004; 37:525-35.
12. Izawa H, Murohara T, Nagata K, et al. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation 2005; 112:2940-5.
13. Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000; 102:2700-6.
14. Iraqi W, Rossignol P, Angioi M, et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation 2009; 119:2471-9.
15. Zannad F, McMurray JJ, Krum H, et al. the EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364:11-21.
16. Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, et al. Beneficial effect of aldosterone antagonism on left ventricular function and structure and fibrosis markers in the metabolic syndrome - a randomized trial. J Am Coll Cardiol Cardiovasc Imaging 2011; 4:1239-49.
17. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. PLoS Med 2010; 7:e1000251.
18. Lang RM, Bierig M, Devereux RB, et al. Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography. J Am Soc Echocardiogr 2005; 18:1440-63.
19. Mottram PM, Haluska B, Leano R, et al. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 2004; 110:558-65.
20. Di Bello V, Santini F, Di Cori A, et al. Obesity cardiomyopathy: is it a reality? An ultrasonic tissue characterization study. J Am Soc Echocardiogr 2006; 19:1063-71.
21. Vasan RS. Cardiac function and obesity. Heart 2003; 89:1127-9.
22. Peterson LR, Herrero P, Schechtman KB, et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 2004; 109:2191-6.
23. Laviades C, Varo N, Díez J. Transforming growth factor beta in hypertensives with cardiorenal damage. Hypertension 2000; 36:517-22.
24. Robert V, Silvestre JS, Charlemagne D, et al. Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension 1995; 26:971-8.
25. Brilla CG. Renin-angiotensin-aldosterone system and myocardial fibrosis. Cardiovasc Res 2000; 47:1-3.
26. Díez J, Laviades C. Monitoring fibrillar collagen turnover in hypertensive heart disease. Cardiovasc Res 1997; 35:202-5.
27. López B, Querejeta R, Varo N, et al. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001; 104:286-91.
28. Díez J, Panizo A, Gil MJ, et al. Serum markers of collagen type I metabolism in spontaneously hypertensive rats: relation to myocardial fibrosis. Circulation 1996; 93:1026-32.
29. Uusimaa P, Risteli J, Niemelä M, et al. Collagen scar formation after acute myocardial infarction: relationships to infarct size, left ventricular function, and coronary artery patency. Circulation 1997; 96:2565-72.
30. Peuhkurinen KJ, Risteli L, Melkko JT, et al. Thrombolytic therapy with streptokinase stimulates collagen breakdown. Circulation 1991; 83:1969-75.